thalidomide has been researched along with cyclin d1 in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horrobin, DF | 1 |
| Aggarwal, BB; Bhutani, M; Guha, S; Kunnumakkara, AB; Nair, AS; Pathak, AK; Sethi, G | 1 |
| Asaoku, H; Katayama, Y; Kimura, A; Kuroda, Y; Matsui, H; Mizuno, M; Munemasa, S; Nakaju, N; Nishisaka, T; Ogawa, K; Okikawa, Y; Sakai, A; Tanaka, H; Tsuyama, N | 1 |
| Baz, R; Cook, JR; Hussein, M; Karafa, M; Kelley, TW | 1 |
| Bauer, F; Dasanu, CA; Reale, MA | 1 |
| Bjorklund, CC; Davis, RE; Kornblau, SM; Kuhn, DJ; Ma, W; Orlowski, RZ; Shah, JJ; Wang, M; Wang, ZQ | 1 |
| Skarbnik, AP; Smith, MR | 1 |
| Bustany, S; Cahu, J; Colomer, D; Martínez, A; Moros, A; Roué, G; Saborit-Villarroya, I; Sola, B | 1 |
| Body, S; Bourgeais, J; Bustany, S; Gouilleux, F; Hérault, O; Sola, B; Tchakarska, G | 1 |
| Chen, C; Gao, G; He, L; Ma, Z; Xu, K | 1 |
1 review(s) available for thalidomide and cyclin d1
| Article | Year |
|---|---|
Therapies for mantle cell lymphoma: current challenges and a brighter future.
Topics: Antibodies; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Cyclin D1; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Recurrence; Thalidomide; TOR Serine-Threonine Kinases; Translocation, Genetic; Treatment Outcome | 2013 |
9 other study(ies) available for thalidomide and cyclin d1
| Article | Year |
|---|---|
A low toxicity maintenance regime, using eicosapentaenoic acid and readily available drugs, for mantle cell lymphoma and other malignancies with excess cyclin D1 levels.
Topics: Angiogenesis Inhibitors; Cell Cycle; Clotrimazole; Cyclin D1; Cyclooxygenase Inhibitors; Eicosapentaenoic Acid; Humans; Lymphoma, Mantle-Cell; Protein Biosynthesis; Thalidomide | 2003 |
Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Capsaicin; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cell Proliferation; Cyclin D1; DNA; Extracellular Signal-Regulated MAP Kinases; G1 Phase; Humans; Inhibitor of Apoptosis Proteins; Interleukin-6; Janus Kinase 1; Microtubule-Associated Proteins; Multiple Myeloma; Neoplasm Proteins; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; STAT3 Transcription Factor; Survivin; Thalidomide; Vascular Endothelial Growth Factor A | 2007 |
Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin D2; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Dexamethasone; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Phosphorylation; Pyrazines; Retinoblastoma Protein; Thalidomide; Time Factors; Transfection; Up-Regulation; Vincristine | 2008 |
Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Nucleus; Clinical Trials, Phase II as Topic; Cyclin D1; Dexamethasone; Doxorubicin; Female; Fibroblast Growth Factor 3; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Ohio; Polyethylene Glycols; Survival Rate; Thalidomide; Tumor Suppressor Protein p53; Vincristine | 2009 |
Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclin D1; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppression Therapy; Lenalidomide; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Second Primary; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous | 2010 |
Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.
Topics: Antineoplastic Agents; beta Catenin; Casein Kinase Ialpha; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lenalidomide; Multiple Myeloma; Plasma Cells; Proto-Oncogene Proteins c-myc; Signal Transduction; Thalidomide; Transcription, Genetic; Wnt Proteins; Wnt3 Protein; Wnt3A Protein | 2011 |
Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Female; Gene Expression; Heterografts; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Mice; Middle Aged; Protein Binding; Protein Stability; Thalidomide; Tumor Burden | 2014 |
Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells.
Topics: Cell Adhesion; Cell Line, Tumor; Cell Movement; Chemokines; Cyclin D1; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Humans; Multiple Myeloma; Oxidation-Reduction; Oxidative Stress; Reactive Oxygen Species; Thalidomide; Tumor Microenvironment | 2016 |
ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma.
Topics: Apoptosis; Azepines; bcl-X Protein; Carcinoma; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin D1; Humans; Proteolysis; Proto-Oncogene Proteins c-myc; Thalidomide; Thyroid Neoplasms; Transcription Factors | 2020 |